Company Analysis Atea Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (3.27 $) is less than fair price (4.93 $)
- The stock's return over the last year (-8.15%) is higher than the sector average (-31.05%).
Disadvantages
- Dividends (0%) are below the sector average (0.5473%).
- Current debt level 0.4037% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-24.49%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Atea Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.8% | -22.6% | 2.4% |
| 90 days | -7.4% | -35.5% | 5.7% |
| 1 year | -8.1% | -31% | 31.6% |
AVIR vs Sector: Atea Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 22.9% over the past year.
AVIR vs Market: Atea Pharmaceuticals, Inc. has significantly underperformed the market by -39.73% over the past year.
Stable price: AVIR is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: AVIR with weekly volatility of -0.1567% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (3.27 $) is lower than the fair price (4.93 $).
Price significantly below the fair price: The current price (3.27 $) is 50.8% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (11.38) is lower than that of the sector as a whole (48.72).
P/E vs Market: The company's P/E (11.38) is lower than that of the market as a whole (49.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.4776) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (0.4776) is lower than that of the market as a whole (3.18).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.7) is lower than that of the sector as a whole (33.75).
P/S vs Market: The company's P/S indicator (1.7) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.7558) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.7558) is lower than that of the market as a whole (28.35).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 229.46% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (229.46%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (123.79%).
5.4. ROE
ROE vs Sector: The company's ROE (-24.49%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-24.49%) is lower than that of the market as a whole (10.67%).
5.5. ROA
ROA vs Sector: The company's ROA (-22.85%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-22.85%) is lower than that of the market as a whole (6.44%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.58%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (7.58%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5473%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 19.09.2024 | Sommadossi Jean-Pierre President, CEO, and Chairman |
Sale | 4 | 7 364 | 1 841 |
| 18.09.2024 | Sommadossi Jean-Pierre President, CEO, and Chairman |
Sale | 4.03 | 89 414 | 22 187 |
| 17.09.2024 | Sommadossi Jean-Pierre President, CEO, and Chairman |
Sale | 4.05 | 137 461 | 33 941 |
| 01.02.2024 | Hammond Janet MJ Chief Development Officer |
Sale | 3.84 | 53 871 | 14 029 |
| 01.02.2024 | Vavricka John Chief Commercial Officer |
Sale | 3.84 | 45 385 | 11 819 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
